Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Oneview Healthcare Adds Six Customers as Bedside Hub Gains Traction
Oneview Healthcare adds six customers, with four Bedside Hub deals already meeting its second-half target as US hospital demand builds.
Latest Stories — SECTOR DESK
Resonance Health Raises $6m to Develop Liver Fibrosis Software
Resonance Health raises $6m as preliminary results show its MRI software can identify significant liver fibrosis, targeting drug trials.
Dimerix Gains New Human Evidence Supporting DMX-200 Kidney Disease Target
Dimerix gains human evidence linking CCR2 activity to poorer FSGS outcomes, strengthening the rationale for DMX-200 as its Phase 3 ACTION3 trial progresses.
Recce Pharmaceuticals Signs Exclusive Deal with Arrotex for 327 Topical Gel
Recce Pharmaceuticals signs exclusive Arrotex deal for RECCE 327 gel in Australia and New Zealand, with launch dependent on trial success and approval.
Cleo Diagnostics Exceeds Performance Targets in First PoC Study of Ovarian Cancer Screening Test
Cleo Diagnostics’ ovarian cancer screening test beats targets, delivering 92.2% sensitivity and 98.7% specificity in its first proof-of-concept study.
Starpharma Boosts Stake in Petalion Therapeutics to Lead Dendrimer-Enhanced Oncology Program
Starpharma lifts its Petalion stake to 66%, taking control of the FAP-targeted cancer program and committing up to $5m to advance development.
Argenica Therapeutics Strengthens Case for Xaranetide Limiting Damage from Acute Brain Injuries
Argenica Therapeutcis says new studies strengthen evidence Xaranetide can reversibly block damaging NMDA activity after acute brain injury.
Pacific Edge Advances US Recovery with Medicare Pricing Boost and Insurer Contracts
Pacific Edge secures new US insurer contracts as proposed Medicare rates rise up to 39%, advancing its bladder cancer testing recovery.
Austco Healthcare Expands Software Reach with $15m RTM Acquisition
Austco Healthcare is acquiring RTM for an estimated $15.26m, adding monitoring software used at 600+ Australian sites and expanding recurring revenue potential.
Medical Developments International Reports Stronger Penthrox Demand across Multiple Regions
Medical Developments International’s Penthrox volumes rose 37% in Europe and 24% in Australian hospitals, despite quarterly revenue falling $700,000 to $10.2m.
Clever Culture Systems Taps PSC Biotech to Expand APAS Independence Pharma Sales
Clever Culture Systems appoints PSC Biotech as sole sales agent for APAS Independence, targeting pharmaceutical makers in the US, Canada and Singapore.
PainChek Expands Sabra Health US Rollout To 23 Care Communities
PainChek expands Sabra US rollout to 23 care communities, securing 808 contracted memory care licences as it targets year-end activation.